WallStSmart

CryoCell International Inc (CCEL)vsTenet Healthcare Corporation (THC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Tenet Healthcare Corporation generates 69972% more annual revenue ($21.81B vs $31.13M). THC leads profitability with a 10.3% profit margin vs -7.9%. CCEL appears more attractively valued with a PEG of 1.34. THC earns a higher WallStSmart Score of 74/100 (B).

CCEL

Buy

50

out of 100

Grade: C-

Growth: 5.3Profit: 5.5Value: 7.0Quality: 5.5
Piotroski: 6/9Altman Z: -0.53

THC

Strong Buy

74

out of 100

Grade: B

Growth: 6.7Profit: 8.0Value: 6.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCELUndervalued (+33.9%)

Margin of Safety

+33.9%

Fair Value

$5.05

Current Price

$3.99

$1.06 discount

UndervaluedFair: $5.05Overvalued

Intrinsic value data unavailable for THC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEL3 strengths · Avg: 10.0/10
Return on EquityProfitability
129.2%10/10

Every $100 of equity generates 129 in profit

EPS GrowthGrowth
72.1%10/10

Earnings expanding 72.1% YoY

Debt/EquityHealth
-0.5010/10

Conservative balance sheet, low leverage

THC3 strengths · Avg: 10.0/10
P/E RatioValuation
10.1x10/10

Attractively priced relative to earnings

Return on EquityProfitability
48.1%10/10

Every $100 of equity generates 48 in profit

EPS GrowthGrowth
213.4%10/10

Earnings expanding 213.4% YoY

Areas to Watch

CCEL4 concerns · Avg: 2.0/10
Market CapQuality
$35.48M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-1.9%2/10

Revenue declined 1.9%

Altman Z-ScoreHealth
-0.532/10

Distress zone — elevated risk

Profit MarginProfitability
-7.9%1/10

Currently unprofitable

THC3 concerns · Avg: 3.0/10
PEG RatioValuation
1.824/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.734/10

Distress zone — elevated risk

Debt/EquityHealth
2.841/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEL

The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.

Bull Case : THC

The strongest argument for THC centers on P/E Ratio, Return on Equity, EPS Growth.

Bear Case : CCEL

The primary concerns for CCEL are Market Cap, Revenue Growth, Altman Z-Score.

Bear Case : THC

The primary concerns for THC are PEG Ratio, Altman Z-Score, Debt/Equity. Debt-to-equity of 2.84 is elevated, increasing financial risk.

Key Dynamics to Monitor

CCEL profiles as a turnaround stock while THC is a value play — different risk/reward profiles.

THC carries more volatility with a beta of 1.23 — expect wider price swings.

THC is growing revenue faster at 6.8% — sustainability is the question.

THC generates stronger free cash flow (417M), providing more financial flexibility.

Bottom Line

THC scores higher overall (74/100 vs 50/100). CCEL offers better value entry with a 33.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CryoCell International Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.

Tenet Healthcare Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Tenet Healthcare Corporation is a diversified health services company. The company is headquartered in Dallas, Texas.

Want to dig deeper into these stocks?